Seattle Genetics investors breathe a sigh of relief as Adcetris posts 30% sales growth
admin 17th July 2019 Uncategorised 0If Seattle Genetics’ second-quarter earnings report is any indication, the company’s lead product is finally living up to its potential. The company unveiled that sales of cancer drug Adcetris jumped 30% year-over-year to $159 million in the U.S. and Canada, handily beating the consensus estimate of $148 million.
More: Seattle Genetics investors breathe a sigh of relief as Adcetris posts 30% sales growth
Source: fierce